# Metabolism and Pharmacokinetics of [14C] BEA 2180 BR Administered Orally Compared to [14C] BEA 2180 BR Administered Intravenously in Healthy Male Volunteers

> **NCT02258971** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 14 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BEA 2180 BR oral
- **DRUG:** BEA 2180 BR infusion

## Key facts

- **NCT ID:** NCT02258971
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2007-05
- **Final completion:** —
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2014-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02258971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02258971, "Metabolism and Pharmacokinetics of [14C] BEA 2180 BR Administered Orally Compared to [14C] BEA 2180 BR Administered Intravenously in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02258971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*